Astrazeneca Phar

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE203A01020
  • NSEID: ASTRAZEN
  • BSEID: 506820
INR
8,429.00
139.15 (1.68%)
BSENSE

Mar 25

BSE+NSE Vol: 5.71 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Acutaas Chemical
Sai Life
Emcure Pharma
J B Chemicals &
Natco Pharma
Gland Pharma
Pfizer
ERIS Lifescience
Astrazeneca Phar
Piramal Pharma
Wockhardt

Why is Astrazeneca Pharma India Ltd ?

1
Flat results in Dec 25
  • PAT(Q) At Rs 31.55 cr has Fallen at -45.6% (vs previous 4Q average)
  • CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 399.94 cr
  • PBDIT(Q) Lowest at Rs 44.83 cr.
2
With ROE of 26.1, it has a Very Expensive valuation with a 26.4 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 0.01%, its profits have risen by 16.3% ; the PEG ratio of the company is 6.2
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Astrazeneca Phar for you?

Medium Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Astrazeneca Phar
0.01%
0.00
30.29%
Sensex
-3.52%
-0.27
12.93%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
22.23%
EBIT Growth (5y)
22.08%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.88
Tax Ratio
26.29%
Dividend Payout Ratio
69.12%
Pledged Shares
0
Institutional Holding
8.27%
ROCE (avg)
97.56%
ROE (avg)
21.62%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
101
Industry P/E
32
Price to Book Value
26.37
EV to EBIT
83.90
EV to EBITDA
72.03
EV to Capital Employed
47.73
EV to Sales
9.51
PEG Ratio
6.22
Dividend Yield
0.38%
ROCE (Latest)
63.10%
ROE (Latest)
26.07%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
ROCE(HY)

Highest at 37.81%

NET SALES(Q)

Highest at Rs 611.57 cr

-11What is not working for the Company
PAT(Q)

At Rs 31.55 cr has Fallen at -45.6% (vs previous 4Q average

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 399.94 cr

PBDIT(Q)

Lowest at Rs 44.83 cr.

OPERATING PROFIT TO NET SALES (Q)

Lowest at 7.33%

PBT LESS OI(Q)

Lowest at Rs 39.93 cr.

Loading Valuation Snapshot...

Here's what is working for Astrazeneca Phar

Net Sales - Quarterly
Highest at Rs 611.57 cr and Grown
each quarter in the last five quarters
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 611.57 cr has Grown at 21.9% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 501.54 Cr
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Here's what is not working for Astrazeneca Phar

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 39.93 cr has Fallen at -41.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 67.84 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 31.55 cr has Fallen at -45.6% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 58.05 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Lowest at Rs 44.83 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Lowest at 7.33%
in the last five quarters
MOJO Watch
Company's efficiency has deteriorated

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 39.93 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Cash and Cash Equivalents - Half Yearly
Lowest at Rs 399.94 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents